Author:
Bouchal Siham,Oubelkacem Naoual,Lahmadi Nabila,Berradi Rhizlane,Belahsen Faouzi
Publisher
Scientific Research Publishing, Inc.
Reference9 articles.
1. Clerico, M., et al. (2017) Long-Term Safety Evaluation of Natalizumab for the Treatment of MS Expert Opinion on Drug Safety. Expert Opinion on Drug Safety, 16.
2. Natalizumab for induction of remission in Crohn's disease
3. Anti-integrin therapy for inflammatory bowel disease
4. Bresch, S., Cohen, M., Rocher, F., Laffon, M., Thomas, P. and Lebrun, C. (2012) Anomalies hématologiques du natalizumab et sa signification Clinique. Revue Neurologique, 168, 116-120.
5. Severe haematological complications during treatment with natalizumab